Table 3. Kitagawa-Blinder-Oaxaca Decomposition of AET Adherence (Proportion of Days Covered).
| Model | Black | White | Mean (95% CI) | ||
|---|---|---|---|---|---|
| Net difference (White) - (Black) | Explained Difference | Unexplained Difference | |||
| Baseline modela | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.7 (–0.1 to 11.6) | –2.3 (–9.9 to 5.4) |
| Baseline model adjusted for symptom clusters | |||||
| Gastrointestinal symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.1 (–0.1 to 10.8) | –1.6 (–9.1 to 6.0) |
| Gynecological symptomsb | 78.8 | 82.5 | 3.6 (–1.5 to 8.7) | 5.7 (–0.1 to 11.5) | –2.1 (–9.7 to 5.6) |
| Neuropsychological symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.8 (–0.1 to 11.8) | –2.4 (–10.1 to 5.4) |
| Vasomotor symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.6 (–0.2 to 11.4) | –2.1 (–9.8 to 5.5) |
| Musculoskeletal symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 4.9 (–0.9 to 10.8) | –1.5 (–9.1 to 6.2) |
| Integumentary symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.6 (–0.2 to 11.3) | –2.1 (–9.7 to 5.5) |
| Cardiorespiratory symptomsb | 78.8 | 82.3 | 3.5 (–1.6 to 8.6) | 5.4 (–0.4 to 11.2) | –1.9 (–9.5 to 5.7) |
| Distress symptomsb | 79.1 | 81.7 | 2.6 (–2.9 to 8.1) | 7.5 (1.2 to 13.9) | –4.9 (–13.0 to 3.2) |
| Despair symptomsb | 79.1 | 81.7 | 2.6 (–2.9 to 8.0) | 8.1 (1.8 to 14.4) | –5.5 (–13.6 to 2.6) |
Abbreviation: AET, adjuvant endocrine therapy.
a
Baseline model was adjusted for sociodemographic characteristics (age at diagnosis, race, neighborhood-level education, neighborhood-level income, residence state, insurance status), clinical characteristics (cancer stage, history of chemotherapy to AET initiation), and first AET drug type.
b
Model was adjusted for sociodemographic characteristics and clinical characteristics in baseline model, as well as corresponding symptom cluster (eg, neuropsychological symptoms, vasomotor symptoms, musculoskeletal symptoms, cardiorespiratory symptoms, distress symptoms).